AKT1 and breast carcinoma: In addition, another study revealed that the PI3K/AKT pathway promoted the expression of IGFBP2 in MCF-7 breast cancer cells, and LY294002 (a PI3K inhibitor) directly reduced IGFBP2 production via the SP-1, which is a transcription factor involved in IGFBP2 [30].